Related Experiment Video
Updated: Jun 1, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Cytokine gene polymorphism and asthma susceptibility, progress and control level
Saeed Daneshmandi1, Ali Akbar Pourfathollah, Zahra Pourpak
1Department of Immunology, Tarbiat Modares University, Faculty of Medical Sciences, Tehran, Iran.
Molecular Biology Reports
|June 4, 2011
Summary
Tumor necrosis factor-alpha (TNF-α) gene variants are linked to asthma risk and reduced lung function. However, these cytokine gene variations do not impact asthma control or IgE levels.
Area of Science:
- Immunogenetics
- Respiratory Medicine
- Molecular Biology
Background:
- Asthma is a complex inflammatory condition influenced by genetic and environmental factors.
- Cytokines play a crucial role in asthma pathophysiology, affecting disease development and severity.
- Understanding the genetic basis of cytokine variations is key to managing asthma effectively.
Purpose of the Study:
- To investigate the association between specific cytokine gene polymorphisms and asthma susceptibility.
- To evaluate the impact of these polymorphisms on asthma control and lung function parameters.
- To explore the relationship between cytokine gene variants and serum immunoglobulin E (IgE) levels.
Main Methods:
- Genotyping of IL-4-C590T, IFN-γ T+874A, TNF-α-A308G, IL-6 G-174C, and TGF-β T+869C variants using PCR-based methods.
- Measurement of serum IgE levels via ELISA.
- Analysis of asthma diagnosis, control, and lung function (FEF25-75, FVC) in 81 asthmatic patients and 124 controls.
Main Results:
- The TNF-α-308GA genotype was significantly more frequent in asthmatic patients, indicating a risk factor (P = 0.025).
- IFN-γ+874AT genotype showed a positive correlation with a family history of asthma (P = 0.034).
- Certain genotypes (IL-6-174C, TNF-α-308GG, TNF-α-308G) were associated with reduced pulmonary function, while TNF-α-308GA increased FEF25-75; IFN-γ+874AA decreased FVC.
Conclusions:
- TNF-α-308GA is identified as a risk factor for asthma development.
- Cytokine gene variants do not appear to influence asthma control levels or serum IgE.
- Reduced expression variants of IL-6, TNF-α, and IFN-γ correlate with diminished lung function capacity.
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...